ArticleCancer research2008
Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Guideline
- Dynamics ofGut · 2018Trial
- Bad bugs mean business: gastric cancer is an intended consequence ofInfection and immunity · 2026Review
- The emerging role of non-Gastroenterology report · 2026Review
- Evaluation of the Rapid Urease Test (RUT) Device for Rapid Diagnosis ofMicroorganisms · 2025Article
- TRIF-IFN-I pathway iniScience · 2024Article
- Characterization of cytotoxic Citrobacter braakii isolated from human stomach.FEBS open bio · 2024Article
- Review
- Comparison of genomic and transcriptional microbiome analysis in gastric cancer patients and healthy individuals.World journal of gastroenterology · 2023Article
- Gastric microbiota: an emerging player in gastric cancer.Frontiers in microbiology · 2023Review
- The role of gastric microecological dysbiosis in gastric carcinogenesis.Frontiers in microbiology · 2023Review
- Cancer-Associated Microbiota: From Mechanisms of Disease Causation to Microbiota-Centric Anti-Cancer Approaches.Biology · 2022Review
- Article
- Oral and gastric microbiome in relation to gastric intestinal metaplasia.International journal of cancer · 2022Article
- The Role of Gut Microbiota in Gastrointestinal Tract Cancers.Archivum immunologiae et therapiae experimentalis · 2022Review
- Explore and Analyze the Composition and Characteristics of Intestinal Microbiota between Gastric Cancer Patients and Healthy People.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021Article
- Review
- The Microbiome and Its Implications in Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2021Review
- Towards Understanding of Gastric Cancer Based upon Physiological Role of Gastrin and ECL Cells.Cancers · 2020Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Helicobacter pylori infection results in chronic gastritis, which may progress to gastric cancer. In this study, we investigated the efficacy of H. pylori eradication in preventing the progression of gastritis to gastric cancer in H. pylori-infected transgenic INS-GAS mice. H. pylori infection induced severe dysplasia and gastric cancer classified as high-grade and low-grade gastrointestinal intraepithelial neoplasia (GIN) in INS-GAS mice at 28 weeks postinfection (WPI). H. pylori eradication therapy using omeprazole, metronidazole, and clarithromycin was administered p.o. at 8, 12, or 22 WPI. Compared with untreated infected mice, H. pylori eradication at 8, 12, and 22 WPI significantly reduced the severity of dysplasia (P < 0.01). Moreover, H. pylori eradication at 8 WPI completely prevented the development of GIN (P < 0.001). Although not as effective as early antimicrobial treatment, prevention of progression to high-grade GIN was achieved by H. pylori eradication at 12 and 22 WPI (P < 0.05). Consistent with reduced gastric pathology, H. pylori eradication at all time points significantly down-regulated gastric Interferon-gamma, tumor necrosis factor-alpha, inducible nitric oxide synthase, and Reg 1 mRNA levels (P < 0.05) and reduced epithelial proliferation in the corpus (P < 0.01) compared with untreated infected mice. We concluded that H. pylori eradication prevented gastric cancer to the greatest extent when antibiotics are given at an early point of infection, but that eradication therapy given at a later time point delayed the development of severe dysplastic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.